Prokidney Corp. · NASDAQ:PROK
Prokidney — Social Capital Suvretta Holdings Corp. III — SPAC Merger (January 2022)
19 slides from Prokidney's SPAC merger presentation, Jan 18, 2022
Slide 1: Chamath Palihapitiya tweet 1/: chronic kidney disease
Chamath Palihapitiya @ @chamath 1/ Chronic kidney disease (CKD) is one of the most prevalent medical conditions, affecting more than 1 in 7 U.S. adults (as well as my late father). We spend up to $500B/yr to treat CKD with drugs and dialysis, which may incrementally slow down the disease but not rev
Slide 2: Chamath Palihapitiya tweet 2/: partnership with ProKidney
Chamath Palihapitiya @ @chamath 2/ Today we partnered with ProKidney, which is changing how we treat CKD. Their clinical data shows its treatment can not only significantly slow the onset of CKD compared to existing therapies, but even REVERSE the loss of kidney function, a first for CKD patients 7:
Slide 3: Chamath Palihapitiya tweet 3/: taking ProKidney public
[yA Chamath Palihapitiya @ @chamath 3/ By taking ProKidney public, they will have the capital to continue Phase 3 clinical trials which have already commenced this month. We are excited to work with a company that has the opportunity to change how millions of people worldwide cope with this terrible
Slide 4: Investment Thesis for ProKidney – Bending the Curve on Chronic Kidney Disease
-2- Investment Thesis for ProKidney – Bending the Curve on Chronic Kidney Disease Overview • Chronic kidney disease (“CKD”) is one of the most prevalent and expensive medical conditions to treat, affecting more than 1 in 7 adults in the U.S. alone • Under the current standard of care, patients and p
Slide 5: Social Capital: Bending the curve on chronic kidney disease
Social Capital @ Sa @socialcapital Bending the curve on chronic kidney disease (CKD) For decades, healthcare providers have been limited to addressing the symptoms of CKD - largely through burdensome regimens like dialysis — with no cure for the underlying disease. Until now. @ Bloomberg @ @business
Slide 6: Conference call transcript, January 18, 2022
January 18, 2022 Corporate Speakers: • Chamath Palihapitiya; Founder & CEO; Social Capital Suvretta Holding Corp. III • Pablo Legorreta; Board Chairman; ProKidney • Kishen Mehta; President; Social Capital Suvretta Holdings Corp. III • Tim Bertram; Chief Executive Officer; ProKidney PRESENTATION Oper
Slide 7: All Hands Meeting – Tim Bertram, Chief Executive Officer
All Hands Meeting – Company Update January 2022 Tim Bertram, Chief Executive Officer
Slide 8: Today's Agenda
Announcement Overview What is a SPAC & Why Social Capital Suvretta? What’s Next? What this Means for You Important Communications Guidelines Closing Remarks Q&A Today’s Agenda 3
Slide 9: Announcement Overview
Announcement Overview ProKidney will become a publicly traded company via a business combination with a special purpose acquisition company – or SPAC – called Social Capital Suvretta, or SCS. This transaction is expected to provide ProKidney with up to $825 million to fund REACT’s Phase 3 developmen
Slide 10: Rationale
Rationale At ProKidney, we are on the forefront of something monumental. Now is the right time for us to take this crucial step. Raising capital through the public markets will provide us access to additional funding and resources, supporting REACT’s Phase 3 development program as well as our eventu
Slide 11: What is a SPAC?
What is a SPAC? Opportunity to vastly improve the quality of life for more than 75M people with CKD in the U.S. and EU, as well as millions of other people around the world SPACs are companies that raise money from public market investors and then merge with a private operating company – in this cas
Slide 12: Why Social Capital Suvretta?
Why Social Capital Suvretta? Management Team Chamath Palihapitiya Founder and CEO, Social Capital Chamath Palihapitiya is Founder and CEO of Social Capital, whose mission is to advance humanity by solving the world’s hardest problems. Kishen Mehta Portfolio Manager of the Averill strategy, Suvretta
Slide 13: What's Next?
What’s Next? Transaction will close in the third quarter of 2022, subject to approval by SCS’s shareholders and other customary closing conditions.
Slide 14: What this Means for You
What this Means for You For the vast majority of you, your day-to-day responsibilities will not change. Everything remains business as usual – our executive leadership team, your roles, and managers will all remain the same. Our executive leadership team and Board of Directors will work closely with
Slide 15: Important Communications Guidelines
Important Communications Guidelines As a public company, we may receive more attention than we have previously, and we are all more restricted in what we can say about ProKidney and this transaction than we were before. If you receive any inquiries from external parties, please refer them to our ann
Slide 16: Thank You
CONFIDENTIAL Prokioney: Thank You
Slide 17: Q&A
CONFIDENTIAL Prokione\ Q&A
Slide 18: Additional Information and Where to Find It
Additional Information and Where to Find It In connection with the proposed transaction, Social Capital Suvretta Holdings Corp. III (“SCS”) intends to file a preliminary proxy statement and a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”). SHAREHOLDERS OF SCS
Slide 19: Forward-Looking Statements
Forward-Looking Statements This communication may contain certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between ProKidney and SCS. These forward-looking statements generally are identified by the words “believe,” “projec
Social Capital Suvretta Holdings Corp. III — SPAC Merger (January 2022) on 6ix